4.54

0.00% 0.03

Orchestra Biomed Holdings Inc (OBIO)

Overview News Price History Discussions Forecast

Orchestra Biomed Holdings Inc stock is traded at $4.54, with a volume of 118.17K. It is up +0.00% in the last 24 hours and up +13.32% over the past month. Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Previous Close:

$4.51

Open:

$4.38

24h Volume:

118.17K

Relative Volume:

0.57

Market Cap:

$264.81M

Revenue:

$2.76M

Net Income/Loss:

$-49.12M

P/E Ratio:

-3.0267

EPS:

-1.5

Net Cash Flow:

$-46.21M

1W Performance:

+2.97%

1M Performance:

+13.32%

6M Performance:

+84.84%

1Y Performance:

+1.81%

1-Day Range:

$4.38

$4.60

1-Week Range:

$4.09

$4.72

52-Week Range:

$2.20

$5.424

Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile

Name

Orchestra Biomed Holdings Inc

Sector

Healthcare (1121)

Industry

Biotechnology (620)

Phone

646-343-9298

Address

150 UNION SQUARE DRIVE, NEW HOPE

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

OBIO's Discussions on Twitter

Compare OBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OBIO Orchestra Biomed Holdings Inc	4.525	263.93M	2.76M	-49.12M	-46.21M	-1.50
VRTX Vertex Pharmaceuticals Inc	457.26	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	739.25	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.59	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	312.26	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	281.32	31.33B	5.36B	287.73M	924.18M	2.5229

Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Initiated	TD Cowen	Buy
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy
Jan-02-25	Initiated	Barclays	Overweight
Aug-22-24	Initiated	H.C. Wainwright	Buy
Jul-25-24	Initiated	B. Riley Securities	Buy
Jan-19-24	Initiated	Jefferies	Buy
Feb-24-23	Initiated	Piper Sandler	Overweight
Feb-07-23	Initiated	Chardan Capital Markets	Buy

View All

Orchestra Biomed Holdings Inc Stock (OBIO) Latest News

03:49 AM

Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH) - The Globe and Mail

03:49 AM

03:03 AM

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

03:03 AM

Mar 18, 2026

Orchestra BioMed reports 2025 results, advances pivotal clinical trials - MSN

Mar 18, 2026

Aug Highlights: Will Orchestra BioMed Holdings Inc benefit from geopolitical trends2026 Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn

Mar 18, 2026

HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings - MarketBeat

Mar 18, 2026

Mar 17, 2026

Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials - MyChesCo

Mar 17, 2026

Mar 16, 2026

Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 10,000 Shares - MarketBeat

Mar 16, 2026

Mar 14, 2026

Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 13, 2026

Orchestra BioMed (OBIO) First Profitable Quarter Tests Bearish Unprofitability Narrative - simplywall.st

Mar 13, 2026

Orchestra BioMed Holdings (OBIO) Receives a Buy from Chardan Capital - The Globe and Mail

Mar 13, 2026

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm

Mar 13, 2026

Mar 12, 2026